Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
Diagnosis & Disease Information
Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Pembrolizumab Improves Long-term Survival in Advanced Melanoma
Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Immunotherapy Drugs Shows Early Promise in Treating Tumors of Rare, Virus-linked Skin Cancer
Half of 25 patients with Merkel cell carcinoma treated with pembrolizumab experienced significant tumor shrinkage that lasted almost 3 times longer than conventional chemotherapy, and some had no remaining disease after treatment.
Pembrolizumab Achieves Response and Increased Survival in Melanoma
Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.
- Loading...
Loading...
Next post in Melanoma
Loading... 
Loading...